17 May 2024 in Science Advances
Monocytes are immune regulators implicated in the pathogenesis of type 1 diabetes (T1D), an autoimmune disease that targets insulin-producing pancreatic β cells. We determined that monocytes of recent onset (RO) T1D patients and their healthy siblings express proinflammatory/cytolytic transcriptomes and hypersecrete cytokines in response to lipopolysaccharide exposure compared to unrelated healthy controls (uHCs). Flow cytometry measured elevated circulating abundances of intermediate monocytes and >2-fold more CD14 + CD16 + HLADR + KLRD1 + PRF1 + NK-like monocytes among patients with ROT1D compared to uHC. The intermediate to nonclassical monocyte ratio among ROT1D patients correlated with the decline in functional β cell mass during the first 24 months after onset. Among sibling nonprogressors, temporal decreases were measured in the intermediate to nonclassical monocyte ratio and NK-like monocyte abundances; these changes coincided with increases in activated regulatory T cells. In contrast, these monocyte populations exhibited stability among T1D progressors. This study associates heightened monocyte proinflammatory/cytolytic activity with T1D susceptibility and progression and offers insight to the age-dependent decline in T1D susceptibility.
19 May 2022 in Epigenomics
Aims: To evaluate H3K9 acetylation and gene expression profiles in three brain regions of Alzheimer’s disease (AD) patients and elderly controls, and to identify AD region-specific abnormalities. M... Plain language summary Alzheimer’s disease (AD) is the most common form of dementia affecting the elderly population. The onset and progression of AD are influenced by environmental factors, which ...
11 July 2026 in Diabetologia
Aims/hypothesis The development of improved prevention and treatment strategies for type 1 diabetes requires a deeper understanding of its heterogeneity. Our aim was to measure immunological heterogeneity among individuals with new-onset type 1 diabetes using plasma-induced transcription, bioinformatics tools and targeted follow-up analyses. Methods We analysed pre-intervention samples from 560 participants across six immunotherapy trials, using a plasma-induced transcriptional bioassay and a standardised reporter cell population. Results Transcriptomic profiling at baseline identified 2854 transcripts with high variation in at least five trials. Unsupervised clustering divided the participants into two subgroups that did not differ in mean age and whose classifications remained stable in post-baseline longitudinal samples, suggesting that subgroup assignments were not driven by transient relapsing and remitting immune activity (p=1.4 × 10−14). Phenotypic analyses and an independent new-onset type 1 diabetes cohort found subgroup 1 enriched for participants with neutral or low-risk HLA haplotypes and the youngest participants possessing the most rapid rate of C-peptide decline (p<0.05). This subgroup showed elevated plasma cytokine and chemokine levels, increased circulating CD4+CXCR3+CCR6− Th1 T cells (p<0.05) and better therapeutic responses to anti-CD20. Subgroup 2 was enriched for individuals possessing insulin autoantibody titres, higher plasma miR-155-5p and miR-409-3p (p<0.05) and a better therapeutic response to CTLA4-Ig that was linked to a greater reduction in CD4+CD45RO+CD62L+ central memory T cells (p=8.1 × 10−5) and retention of regulatory T cells (p=0.02). Conclusions/interpretation These findings support the existence of immunologically distinct type 1 diabetes subgroups and the possibility of future targeted therapeutic interventions. Data availability All microarray gene expression data files have been deposited at The National Center for Biotechnology Information Gene Expression Omnibus (accession no. GSE302205). Graphical Abstract